Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583908 | 0.83 | CYP2D6 (0.38) | HTR1ASMN1; SMN2HTTCYP2D6LMNA | |
| SCHEMBL5583694 | 0.77 | HTR1A (0.41) | HTR1ACYP1A2MEN1KMT2ATDP1 | |
| SCHEMBL4335133 | 0.73 | LMNA (0.39) | HTR1ASMN1; SMN2HTTCYP2D6LMNA | |
| SCHEMBL4363802 | 0.73 | LMNA (0.39) | HTR1ASMN1; SMN2HTTCYP2D6LMNA | |
| SCHEMBL5583686 | 0.69 | MAPT (0.43) | HTR1AHTTLMNACYP1A2MEN1 | |
| SCHEMBL5583735 | 0.69 | MAPT (0.43) | HTR1AHTTLMNACYP1A2MEN1 | |
| Hydrochloric Acid SCHEMBL5586785 | 0.68 | HTR1A (0.42) | HTR1AHTTLMNACYP1A2MEN1 | |
| SCHEMBL181141 | 0.66 | CYP2D6 (0.54) | SMN1; SMN2CYP2D6CYP1A2MEN1KMT2A | |
| SCHEMBL718466 | 0.65 | CYP2D6 (0.51) | SMN1; SMN2HTTCYP2D6LMNAALDH1A1 | |
| SCHEMBL14439255 | 0.64 | HTR1A (0.39) | HTR1AHTTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HATZENBUHLER NICOLE T | 2007-08-16 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| US-7227023-B2 | Quinoline 3-amino chroman derivatives | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1638976-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | Wyeth (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050004157-A1 | Quinoline 3-amino chroman derivatives | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099214-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191417-A1 | QUINOLINE 3-AMINO CHROMAN DERIVATIVES | HTR3C, HTR3A, HTR2C | HTR1A 5/4885SMN1; SMN2 3082/4885HTT 855/4885 |
| US-20050004157-A1 | Quinoline 3-amino chroman derivatives | HTR3C, HTR3A, HTR2C | HTR1A 5/4885SMN1; SMN2 3082/4885HTT 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.